Bouhnik Y, Carbonnel F, Fumery M, Flamant M, Buisson A, Camoin A, et al. Research article in Digestive and Liver Disease (Juin 2023).
Background : SB5 is an EMA-approved adalimumab biosimilar, having demonstrated bioequivalence, equivalent efficacy, and similar safety and immunogenicity to the reference product.
Aims : Describe patient training and satisfaction using patient-reported outcome measures (PROMs) and assess their impact on 12-month persistence on SB5.
Methods : The observational PERFUSE study included 318 Crohn's disease (CD) patients and 88 ulcerative colitis (UC) patients in 27 sites across France between October 2018 and December 2020. PROMs were collected at 1-month post-baseline using an online questionnaire (ePRO) designed with patient associations. Treatment persistence was collected during routine visits (up to 15 months post-initiation). Results are presented by prior experience with subcutaneous biologics and training in proper use of the injection device.
Results : 57.1% (n = 145) and 44.1% (n = 67) of naïve and pre-treated patients, respectively, answered the ePRO. Naïve patients were offered training more often (86.9% vs 31.3% respectively, p < 0.05), with disparities between sites. All subgroups’ satisfaction scores were high. 12-month persistence on SB5 was significantly higher for respondents than for non-respondents (68.0% [60.9; 74.1] vs 52.3% [44.5; 59.6]; p < 0.05) and in patients with a better perception of their illness (OR=1.02, [1.0; 1.05]; p < 0.05).
Conclusions : Early patient questionnaires may be useful to identify patients at higher risk of treatment discontinuation.
(Publication) Bouhnik Y, Carbonnel F, Fumery M, Flamant M, Buisson A, Camoin A, et al. The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5. Digestive and Liver Disease 2023;0. https://doi.org/10.1016/j.dld.2023.05.025.